Nuveen
APGE

Nuveen’s Apogee Therapeutics APGE Stock Holding History

Nuveen’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5M Buy
131,634
+3,519
+3% +$317K ﹤0.01% 1352
2026
Q1 		$10.8M Buy
128,115
+7,065
+6% +$513K ﹤0.01% 1504
2025
Q4 		$9.14M Buy
121,050
+37,759
+45% +$2.38M ﹤0.01% 1605
2025
Q3 		$3.31M Hold
83,291
– – ﹤0.01% 2100
2025
Q2 		$3.62M Sell
83,291
-27,564
-25% -$1.05M ﹤0.01% 2036
2025
Q1 		$4.14M Sell
110,855
-26,971
-20% -$1.04M ﹤0.01% 2018
2024
Q4 		$6.24M Buy
137,826
+2,480
+2% +$126K ﹤0.01% 1881
2024
Q3 		$7.95M Sell
135,346
-2,552
-2% -$122K ﹤0.01% 1747
2024
Q2 		$5.43M Buy
137,898
+6,376
+5% +$309K ﹤0.01% 1906
2024
Q1 		$8.74M Buy
131,522
+75,799
+136% +$3.31M ﹤0.01% 1680
2023
Q4 		$1.56M Buy
55,723
+38,077
+216% +$763K ﹤0.01% 2524
2023
Q3 		$376K Buy
+17,646
New +$389K ﹤0.01% 2923

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Nuveen's APGE Position: Q2 2026 in Review

Nuveen increased its Apogee Therapeutics (APGE) stake by 2.7% in Q2 2026, buying an estimated $317K and bringing the position to 131,634 shares worth $17.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1352.

Nuveen first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Nuveen held 131,634 shares of Apogee Therapeutics worth $17.5M as of Q2 2026.
  • Nuveen bought 3,519 Apogee Therapeutics shares in Q2 2026, an estimated $317K.
  • Apogee Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1352 holding.
  • Nuveen first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.